ArticleIBRO neuroscience reports2025
Olfactory training in specific anosmia to androstenone and its association with genetic variations of OR7D4.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short-term, repeated exposure to odors, "olfactory training" (OT), improves olfactory function. Clinically, this works not only for trauma- or disease-related olfactory impairment but also in people with specific anosmia. Androstenone is an odorant for which the frequent occurrence of specific anosmia is already known. It is an odorous steroid derived from testosterone. Besides some people who cannot perceive the odor, it is perceived differently by different individuals in terms of odor quality. These differences in the ability to perceive androstenone as well as in the perception of its quality were previously related to single nucleotide polymorphisms of the human olfactory receptor OR7D4. The current study addressed the question of whether changes in the perception of androstenone in relation to a change in sensitivity following specific OT with that odorant are associated with genetic variations of OR7D4. A total of 335 healthy volunteers participated (206 females, 129 males). All participants underwent tests for normal olfactory function; 103 showed specific anosmia for androstenone. Seventy-seven participants initially unable to perceive androstenone performed OT for an average duration of 8 weeks. Detection thresholds as well as subjective evaluation of odor intensity and pleasantness were measured both before and after OT. Buccal swabs were taken to examine the OR7D4 genotype. The study provided the following major results: (1) Detection thresholds were significantly lower after OT. (2) There was no statistically significant impact of the OR7D4 genotype on the ability to perceive androstenone after OT. In conclusion, it appears that the ability to perceive androstenone can be trained in people with specific anosmia, although OR7D4 polymorphisms were not related to a major change in the sensitivity towards androstenone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.